Stifel raised the firm’s price target on OptimizeRx (OPRX) to $16 from $12.50 and keeps a Buy rating on the shares after having hosted CEO Steve Silvestro and CFO Ed Stelmakh at Stifel’s CSI Conference. Management expanded on many key themes from the Q1 earnings report, notes the analyst, who is “encouraged by many of the changes underway, including heightened focus on financial guidance/performance.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Earnings Call: Positive Growth and Strategic Shifts
- OptimizeRx price target raised to $18 from $13 at B. Riley
- OptimizeRx price target raised to $22 from $16 at Roth Capital
- OptimizeRx price target raised to $12.50 from $8 at Stifel
- OptimizeRx price target raised to $14 from $11 at Citizens JMP